Meso
Aftermath
Archived
Pfizer's potential challenge to Lilly's and Novo's GLP-1 duopoly
Activity declining — narrative losing relevance.
Score
0.3
Velocity
▲ 0.0
Articles
13
Sources
3
Sentiment Timeline
Sector Performance
Stock Performance
Event Timeline
Aug 07, 2026
Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy …
Neutral
Jul 20, 2026
Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss …
Neutral
Hypotheses
Pending
Due: Aug. 19, 2026
Pfizer's GLP-1 candidate will fail to meet primary efficacy endpoints in Phase 3 trials or face manufacturing/supply chain delays, pushing commercial launch beyond Q4 2025.
Pending
Due: Oct. 18, 2026
LLY stock will outperform PFE stock by at least 12% over the next 6 months despite GLP-1 competition concerns, as Mounjaro's first-mover advantage and pipeline depth maintain investor confidence.
Pending
Due: Oct. 18, 2026
Pfizer's monthly GLP-1 injection will capture at least 15% market share from Eli Lilly (LLY) and Novo Nordisk (NVO) within 24 months of FDA approval, driven by superior dosing convenience and comparable efficacy data.
Related Articles
Why Pfizer Could Prove to Be an Underrated GLP-1 Stock
Nasdaq
·
Jun 30, 2026
Eli Lilly vs Pfizer: One Owns the Obesity Market Today, The Other Paid to Compete …
Yahoo Finance
·
Jun 24, 2026
Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry …
Nasdaq
·
Jun 12, 2026
Eli Lilly says next-generation weight loss drug clears crucial obesity trial
CNBC
·
May 21, 2026
Is This News From Novo Nordisk a Warning for Eli Lilly Shareholders?
Nasdaq
·
May 09, 2026
A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly
Yahoo Finance
·
Apr 21, 2026
Top Movers
| Ticker | Sector | Change |
|---|---|---|
| Healthcare | +5.4% | |
| Healthcare | +4.8% | |
| Healthcare | -1.1% | |
| Energy | +0.8% |
🤖
AI Overview
What happened: Eli Lilly's (LLY) obesity drug dominance drove Q1 revenue up 55%, while Pfizer's (PFE) growth slowed to 5% due to COVID product declines. Pfizer is challenging Lilly's and Novo Nordisk's (NVO) GLP-1 duopoly, with promising data from its berobenatide and long-acting GLP-1 drug. Lilly's next-generation drug, retatrutide, also showed significant weight loss in late-stage trials.
Market impact: The obesity drug market, valued at over $100 billion, is being disrupted by Pfizer's entry. Lilly and Novo Nordisk, commanding 90% of the market, face potential competition. Pfizer's success could reshape market shares, with Lilly and Novo Nordisk's stocks under pressure. Pfizer's stock, boosted by its pipeline, is a safer bet than smaller GLP-1 stocks.
What to watch next: Lilly's and Novo Nordisk's earnings reports (Q2 2023, expected in late July/early August) will provide updates on their obesity drug sales and market positioning. Pfizer's regulatory filings for its GLP-1 drugs, expected in 2024, will determine its competitive stance.
Market impact: The obesity drug market, valued at over $100 billion, is being disrupted by Pfizer's entry. Lilly and Novo Nordisk, commanding 90% of the market, face potential competition. Pfizer's success could reshape market shares, with Lilly and Novo Nordisk's stocks under pressure. Pfizer's stock, boosted by its pipeline, is a safer bet than smaller GLP-1 stocks.
What to watch next: Lilly's and Novo Nordisk's earnings reports (Q2 2023, expected in late July/early August) will provide updates on their obesity drug sales and market positioning. Pfizer's regulatory filings for its GLP-1 drugs, expected in 2024, will determine its competitive stance.
AI Overview as of Aug 05, 2026
Timeline
First SeenAug 07, 2026
Last UpdatedAug 21, 2026